Idec Pharmaceuticals 1995 Results

4 March 1996

- 1995 was a very good year for Idec Pharmaceuticals, according to William Rastetter, president and chief executive. The firm received revenues from contract research and licensing fees of $23.6 million, up 46%. A net loss was reported in 1995 of $17.3 million or $1.18 per share, which were slight decreases on those in 1994. The 1995 results included a one-time, non-cash charge of $11.4 million for the purchase of technology.

For the fourth quarter of 1995, revenues were $10.7 million, up 234%. Net income in the quarter was $2.7 million or $0.14 per share, compared with a net loss a year earlier of $2.8 million and a loss per share of $0.23.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight